Q32 Bio (QTTB) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Q32 Bio (QTTB) has outperformed Sol-Gel Technologies (SLGL) over the past year, gaining 217.1% versus a gain of 75.5%. Over five years, SLGL leads with a -22.8% price change compared with -92.8% for QTTB. Q32 Bio is the larger company by market cap ($239.0 million vs $229.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QTTB | SLGL |
|---|---|---|
| Share price | $8.03 | $70.13 |
| Market cap | $239.05M | $229.59M |
| 1-day change | +0.50% | -2.53% |
| YTD return | +140.66% | +70.73% |
| 1-year return | +217.06% | +75.52% |
| 5-year return | -92.84% | -22.85% |
| P/E ratio (TTM) | 2.55 | — |
| EPS (TTM) | $3.15 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.57 | $97.97 |
| 52-week low | $1.91 | $28.81 |
| Distance from 52-week high | -65.93% | -28.42% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +393.15% | +117.47% |
| Average volume | 1.37M | 55.30K |
| Shares outstanding | 29.77M | 3.27M |
| Employees | 22 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed SLGL by 141.5 percentage points over the past year.
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
QTTB vs SLGL FAQ
Which is bigger, Q32 Bio or Sol-Gel Technologies?
Q32 Bio (QTTB) is larger, with a market capitalization of $239.05M compared with $229.59M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, QTTB or SLGL?
QTTB returned +217.06% over the past 12 months, compared with +75.52% for SLGL (price return, excluding dividends). Past performance does not predict future results.
Are Q32 Bio and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.